- Home
- SEER vs COEP Comparison
SEER vs COEP Comparison
Compare SEER & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | COEP |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 100.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEER | COEP |
|---|---|---|
| Price | $1.91 | $14.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 198.9K | 94.6K |
| Earning Date | 02-26-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,376,999.00 | $500,996.00 |
| Revenue This Year | $22.37 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $5.70 |
| 52 Week High | $2.45 | $21.41 |
Technical Indicators
Market Signals| Indicator | SEER | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 41.55 |
| Support Level | $1.82 | $13.88 |
| Resistance Level | $1.94 | $16.05 |
| Average True Range (ATR) | 0.06 | 0.78 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 82.35 | 12.93 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.